to bond issuance?. The paper showed positive response of listed companies? share prices to debenture issuance announcement, supported by the trade-off theory, weighting costs and benefits of debt

for capital expenditures as of the latest practicable date. In addition, the registration statement shall indicate the general purpose of such commitments and the anticipated sources of funds needed to

find further information in the consolidated financial statements. 2 Analysis of Costs and Expenses 1. In 2019, Cost of sales was 14,187 MTHB, decreased by 1,462 MTHB comparing to 2018 or 9.3% due the

, The Company’s strategies such as increasing more specialty cilinics, medical instruments and expanding into new market so as to drive a sustainable growth Cost of Hospital Operations The costs of

100.0 15,659 100.0 Sales Revenues 20162017 * Note Please find further information in the consolidated financial statements. 2 Analysis of Costs and Expenses 1. In 2017, Cost of sales was 15,317 MTHB

% 128.86 44% (57.48) -45% Other Revenues & Profit Sharing 60.44 43% 31.57 11% 28.87 91% Selling and admin expenses (91.83) -65% (152.14) -52% (60.31) -40% Financial costs (9.22) -7% (12.21) -4% (2.99) -24

expenses 30 28 2 7% 8.0% 7.3% Finance costs 11 13 (2) -18% Share of loss from associate 0 - Income tax expense (1) 1 (3) Profit for the quarter 17 (7) 24 4.6% (1.8%) Consolidated financial information (Unit

services revenue. Furthermore, the Company and subsidiaries has distribution costs and administration expenses in the amount of THB 401 million, which decreased by THB 325 million from the second quarter of

and beauty treatment services 3,568 43,985 -92% 25,770 72,968 -65% Total revenues from sales and services 435,186 484,581 -10% 759,236 974,275 -22% 4 THB’000 Q2/2020 Q2/2019 ∆% H1/2020 H1/2019 ∆% Costs

32.8% from energy favorable prices. Costs were controlled and the total expenses in quarter 3 reported at Baht 333.6 million, a decrease of 25.9% over the same period last year. As a result, the Company